On demand: advancing on- and off-target deconvolution using capture compound mass spectrometry

Now available to view on demand. Discover capture compound mass spectrometry, an industry-leading chemoproteomics platform for identifying specific-binding protein targets for small molecules with various applications.

Go to the profile of RxNet
Mar 27, 2018

Sponsored by

In this mini-webinar, discover capture compound mass spectrometry (CCMS), an industry-leading chemoproteomics platform for identifying specific-binding protein targets for small molecules with various applications, including target deconvolution, novel target identification and off-target profiling.

Molecular target identification, also known as target deconvolution, is an essential part of the drug discovery process for understanding compound mechanism of action and further optimizing series of chemical matter. CCMS is an unbiased, proteome-wide approach for the identification of specific-binding protein targets for small molecules of interest. The technology combines medicinal chemistry and in vitro pharmacology, coupled to high resolution proteomics mass spectrometry, to isolate and identify target proteins that are responsible for the observed biological response.

What will you learn?

  • Introduction and overview of how the CCMS technology works
  • Advantages of CCMS over traditional affinity pull-down and photoaffinity labelling
  • A range of CCMS applications that is unmatched by any other chemoproteomic technique
  • Target identification in live cell systems, including intracellular and transmembrane proteins
  • Off-target identification using CCMS

Who may this interest?

  • Drug discovery scientists
  • Medicinal chemists
  • Biologists
  • Researchers
  • Pharmacologists


Sam Mann Principal Scientist, Charles River Laboratories.

Sam graduated from the University of York (York, UK) with a Master of Chemistry degree, having spent a year on exchange at the University Joseph Fourier (Grenoble, France). He then moved to London to study for a PhD under the supervision of Dr Tom Sheppard at UCL (London, UK). He later joined Argenta, which became part of Charles River Laboratories (CRL; MA, USA) in 2014. Having worked on a variety of drug discovery programs for high profile clients, he quickly progressed to his current position as a Principal Scientist, leading the medicinal chemistry effort for an integrated drug discovery team. Sam has recently taken on the additional responsibility of chemistry lead on the CCMS team.

Will Stebbeds - Senior Scientist, Charles River Laboratories.

Will Stebbeds graduated from the University of Faro (Faro, Portugal) with a degree in biomedical science and proceeded to do Master’s degrees in bioinformatics and molecular medicine. After completing a PhD in cell biology at Cranfield University (Bedfordshire, UK), including a placement at Unilever (Colworth, UK), Will joined CRL in late 2015, working on a variety of projects from basic science through to high-throughput screening. In this role, Will was promoted within 18 months of arriving at CRL and has led a number of biology projects, focusing principally on phenotypic studies and target deconvolution using CNS disease models. Will is the biology lead on the CCMS team.

Go to the profile of RxNet


A network for the drug discovery and development community, Future Science Group

Your source for the latest news and views from the fields of drug discovery and medicinal chemistry.

No comments yet.